Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kenzo Hiroshima has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Awareness of Partial Loss is Essential in Interpreting Merlin Immunohistochemistry When Diagnosing Pleural Mesothelioma

    by Kazuki Nabeshima, Tomomi Furukawa, Makoto Hamasaki, Kei Kushitani, Yukio Takeshima, Shigeki Shimizu, Kenzo Hiroshima, Maiko Takeda, Hironori Ninomiya, Katsumi Takizawa, et al.

    Ancillary assays, including BAP1 (BRCA‐1‐associated protein 1), MTAP (methylthioadenosine phosphorylase), and Merlin immunohistochemistry (IHC), are effective in discriminating pleural mesothelioma (PM) from reactive mesothelial proliferations (RMP). IHC of Merlin, a protein product of the neurofibromin 2 gene, was most recently developed. Our previous study suggested uneven occurrence of Merlin loss within PM tissues. This was further investigated here in a total of 41 tissues of PM obtained from seven institutions. Partial or diffuse Merlin loss was detected with excellent interobserver agreement (kappa: 0.82). Of the 34 PM cases with interobserver consensus, partial and diffuse loss of Merlin expression were each observed in 13 cases (38%). PM with partial Merlin loss exhibited either discrete or intermingled spatial distribution of Merlin‐lost cells. BAP1 or MTAP showed partial loss in none or only 5% of PM cases, respectively. The diagnostic sensitivity for PM was enhanced to 91% with addition of diffuse and partial Merlin loss to a combination of BAP1 and MTAP loss while maintaining 100% specificity. Although detection of Merlin loss as well as BAP1 and MTAP losses is effective for distinguishing PM from RMP, pathologists should be familiar with partial Merlin loss when interpreting Merlin IHC results.

  • Open Access

    Sarcomatoid Mesothelioma Revealed After Treatment for Tuberculous Pleurisy: A Case Report

    by Daiki Nagayama, Keiki Yokoo, Yousuke Yabushita, Motoki Sekikawa, Masaru Abe, Hiroaki Kato, Ayumi Takayanagi, Bunya Takahashi, Marie Kato‐Shinomiya, Satoshi Ota, et al.

    Differentiating tuberculous (TB) pleurisy from malignant pleural mesothelioma is challenging due to similar clinical presentations. We report an 83‐year‐old man with sarcomatoid mesothelioma initially treated for TB pleurisy. He presented with lymphocyte‐predominant exudative pleural effusion and a positive Interferon‐Gamma Release Assay. Thoracoscopy revealed purulent effusion, but biopsies were non‐diagnostic. Despite empiric anti‐tuberculosis therapy, the effusion persisted. A subsequent surgical biopsy showed fibrosis and scattered spindle cells. However, 2 months later, a rapidly growing chest wall mass with bone invasion appeared. A CT‐guided percutaneous biopsy showed proliferation of atypical spindle cells and fluorescence in situ hybridization (FISH) analysis allowed for the diagnosis of sarcomatoid mesothelioma. This case highlights the aggressive nature of sarcomatoid mesothelioma and its diagnostic difficulty. For treatment‐refractory pleurisy, clinicians must maintain high suspicion, ensuring vigilant follow‐up and prompt repeat biopsies despite negative initial results, while consulting pathologists to consider additional FISH testing.

  • Open Access

    New WHO Reporting System for Lung Cytopathology: Reproducibility Test of the Diagnosis and Usefulness of an Online Tutorial System for the New Cytological Categorization

    by Yuko Minami, Akemi Takenaka, Kenzo Hiroshima, Akihiko Yoshizawa, Reiji Haba, Kunimitsu Kawahara, Yasuo Shibuki, Shinji Miyake, Hirokuni Kakinuma, Yukitoshi Satoh

    Introduction Since no universal cytological classification system for lung cancer has been established, the Japanese Lung Cancer Society and the Japanese Society of Clinical Cytology (JSCC) jointly established and reported four cytological categories: negative for malignancy, atypical cells, suspicious for malignancy, and malignancy. In 2022, the WHO Reporting System for Lung Cytopathology was published. This system presented five cytological classifications, including the four cytological category classifications above and insufficient/inadequate/nondiagnostic. The creation of a classification alone is not practical in actual clinical practice. Thus, we evaluated the reproducibility of the classification through tutorials and identified the issues and problems involved in the wide dissemination of this classification. Methods Forty-two cases were selected from those used in previously published articles, and diagnosis and tutorial systems were created. The first diagnostic round and tutorial and the second diagnostic round were conducted on the web. Participants were recruited via the JSCC website and emails. Images (100× and 400×) of the lesions to be diagnosed were categorizing by 4 cytological categories (benign, atypical, suspicious for malignancy, malignant), 7 suggestive pathological diagnoses, and 4 cytological features. The mean correct or incorrect answer rates for the 42 cases and the mean correct response rates for 105 participants were compared between the first and second rounds using McNemar’s test and t-tests to identify cases with diagnostic difficulties and high tutorial effects. Results Comparing the correct response to cytological categories, the results showed that 17 of 42 cases improved significantly. The mean number of correct answers for the four cytological categories increased significantly from 16.0 (38.1%) in the first round to 20.3 (48.3%) in the second round (p < 0.001). For the seven suggestive pathological diagnoses, the mean number of correct answers increased significantly from 20.3 (48.3%) in the first round to 25.1 (59.8%) in the second round (p < 0.001). The mean number of correct responses increased significantly from 40.2 (38%) in the first round to 51.5 (49%) in the second round (p = 0.0147). Four cases were difficult to match even after the tutorial and three cases were highly affected by the tutorial. The most important basis for diagnoses was nuclear findings in the first and second rounds. Conclusion Comprehensive tutorials on diagnostic criteria are needed to effectively implement this system globally. In particular, devising ways to appropriately diagnose cancers with mild atypia or without characteristic morphology is important.


  • Open Access

    A brief review of the WHO reporting system for lung cytopathology

    by Sule Canberk, Andrew Field, Lukas Bubendorf, Ashish Chandra, Ian A. Cree, Marianne Engels, Kenzo Hiroshima, Deepali Jain, Ivana Kholová, Lester Layfield, et al.


  • Open Access

    Metaplastic breast carcinoma producing prominent basal lamina with neuroendocrine differentiation: A case report

    by Yoshitaka Furuya, Kenzo Hiroshima, Takashi Wakahara, Harutoshi Akimoto, Shigeo Kawai, Masayuki Ota, Yukio Nakatani, Akinori Furuya, Hironobu Yanagie

    Metaplastic breast carcinoma (MBC) is a heterogeneous group of invasive breast carcinomas (IBCs) characterized by the differentiation of the neoplastic epithelium toward squamous cells and/or mesenchymal‑appearing elements. The present study describes the case of a 42‑year‑old woman who underwent a mastectomy and sentinel lymph node biopsy for two tumors in their left breast. One of the resected tumors was diagnosed as MBC with neuroendocrine (NE) differentiation and the other was diagnosed as IBC of no special type. The MBC tumor contained a matrix composed of basal lamina with a focal area of myxoid matrix and squamoid differentiation. To the best of our knowledge, the present study is the first report of MBC producing prominent basal lamina. The patient has remained alive and well for >10 years without recurrence, and has been treated with oral and injected anticancer drugs.

  • Open Access

    Differential Expression of Claudin 1 and 4 in Basal Cell Carcinoma of the Skin

    by T. Nakazawa, A. Hasegawa, T. Nagasaka, K. Yoshida, F. Guo, D. Wu, K. Hiroshima, M. Takeuchi

    Basal cell carcinoma (BCC) is the most common human malignancy. The biological behavior of this entity is remarkably indolent. Claudin plays an important role in tight junctions, regulating paracellular passage of variable substance including growth factors and maintaining the polarity of epithelia. Up- or downregulated claudin expression has been reported in many cancers. Nevertheless, claudin expression in BCC of the skin remains unclear. We therefore examined the status of claudin 1 and 4 expressions in BCC and adjacent normal skin by immunohistochemistry (IHC). Our IHC results demonstrated high claudin 1 expression and low claudin 4 expression in 33 of 34 lower-grade BCCs. In lower-grade BCC, claudin 1 was increased and claudin 4 was decreased compared with the normal skin. Claudin 1 was inclined to be highly expressed in the membrane and cytoplasm of tumour cells in the periphery of tumour nest. Conversely, almost all lower-grade BCCs (33/34) and one of two higher-grade BCC lacked or showed focal positivity for claudin 4. These results imply that the expression pattern is characteristics of lower-risk BCC. Interestingly, one of the two higher-grade BCCs demonstrated the converse expression patterns of claudins, with decreased claudin 1 and increased claudin 4. The combination of immunohistochemical claudin 1 and 4 expression may offer a useful ancillary tool for the pathological diagnosis of BCC. Furthermore, membranous and intracellular claudins may present future therapeutic targets for uncontrollable BCC.


  • The World Health Organization Reporting System for Lung Cytopathology

    by Fernando C. Schmitt, Lukas Bubendorf, Sule Canberk, Ashish Chandra, Ian A. Cree, Marianne Engels, Kenzo Hiroshima, Deepali Jain, Ivana Kholová, Lester Layfield, et al.

    The International Academy of Cytology has joined with the International Agency for Research on Cancer (IARC) to bring together a group of experts in lung cytopathology to develop a WHO Reporting System for Lung Cytopathology (WHO System). This WHO System defines five categories for reporting lung cytopathology, that is, “Insufficient”/“Inadequate”/“Non-diagnostic,” “Benign,” “Atypical,” “Suspicious for malignancy,” and “Malignant,” each with a clear descriptive term for the category, a definition, a risk of malignancy and a suggested management algorithm. The key diagnostic cytopathology features of each of the lesions within each category have been established by consensus and will be presented more fully in a subsequent IARC e-book and published hard cover book.The WHO System provides the best practice application of ancillary testing, including immunocytochemistry and molecular pathology, and provides a review to guide sampling and processing techniques to optimize the handling and preparation of the cytopathology sample emphasizing the cytomorphological differential diagnosis to aid low-resourced settings. The authors recognize that local medical and pathology resources will vary, particularly in low- and middle-income countries, and have developed the WHO System to make it applicable worldwide based on cytomorphology with options for further diagnostic management of the patient.The online WHO System provides a direct link to the WHO Tumour Classification for Thoracic Tumours 5th Edition. It will raise the profile and use of cytopathology by increasing awareness of its current role and its potential role in the era of personalized medicine based on molecular pathology utilizing “small biopsies.” Ultimately, the System will improve patient care and outcomes.This System aims to improve and standardize the reporting of cytopathology, facilitate communication between cytopathologists and clinicians and improve patient care. The System is based on the current role of lung cytopathology and synthesizes the existing evidence while highlighting areas requiring further research and the future potential role of lung cytopathology.


  • Open Access

    A Primary Lung Adenocarcinoma with Predominant Bone Formation

    by Masatoshi Yamaguchi, Hiroki Fukuda, Hiroaki Kashimada, Ato Sugiyama, Kohei Aoki, Tai Hato, Masatoshi Gika, Mitsutomo Kohno, Mitsuo Nakayama, Mami Yamazaki, et al.

    69歳男性.CTで,右肺上葉にほぼ全体を石灰化像が占める不整形結節を認めた.結節は7年前のCTと比べ増大傾向であった.悪性腫瘍も否定できないため胸腔鏡下右肺部分切除術を施行し,術中迅速診断を試みたが薄切不能と判断された.永久標本で骨梁と脂肪髄を有する骨形成を伴う原発性肺腺癌の診断となり,残存右肺上葉切除術,リンパ節郭清を追加した.自験例は,骨形成を伴う原発性肺癌の中でも既存の報告と異なる発育形態を呈していた.

  • Open Access

    Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology: An Extensive Study Containing More Benign Lesions

    by Akihiko Yoshizawa, Kenzo Hiroshima, Akemi Takenaka, Reiji Haba, Kunimitsu Kawahara, Yuko Minami, Hirokuni Kakinuma, Yasuo Shibuki, Shinji Miyake, Kenta Kajio, et al.

    Introduction: The Japan Lung Cancer Society (JLCS) and the Japanese Society of Clinical Cytology (JSCC) have proposed a new four-tiered cytology reporting system for lung carcinoma (JLCS-JSCC system). Prior to the proposal, the Papanicolaou Society of Cytopathology (PSC) had proposed a revised reporting system (PSC system), which comprises the “neoplastic, benign neoplasm, and low-grade carcinoma” category (N-B-LG category), in addition to the 4 categories of the JLCS-JSCC system. This study aimed to evaluate the interobserver agreement of the JLCS-JSCC system with an additional dataset with more benign lesions in comparison with the PSC system. Methods: We analyzed 167 cytological samples, which included 17 benign lesions, obtained from the respiratory system. Seven observers classified these cases into each category by reviewing one Papanicolaou-stained slide per case according to the JLCS-JSCC system and PSC system. Results: The interobserver agreement was moderate in the JLCS-JSCC (k = 0.499) and PSC (k = 0.485) systems. Of the 167 samples, 17 samples were benign lesions: 7 pulmonary hamartomas, 5 sclerosing pneumocytomas, 2 squamous papillomas, one solitary fibrous tumor, one meningioma, and one lymphocytic proliferation. There were diverse sample types as follows: 11 touch smears, 3 brushing smears, 2 aspirations, and one sputum sample. Fourteen samples (82.3%) were categorized into “negative” or “atypical” by more than half of the observers in the JLCS-JSCC system. Conversely, 3 samples were categorized as “suspicious” or “malignant” by more than half of the observers in the JLCS-JSCC system. On the other hand, 11 samples (64.7%) were categorized into the N-B-LG category by more than half of the observers in the PSC system. Conclusions: The concordance rate in the JLCS-JSCC system was slightly higher than that in the PSC system; however, the interobserver agreement was moderate in both the JLCS-JSCC and PSC systems. These results indicate that both the JLCS-JSCC and PSC systems are clinically useful. Therefore, both systems are expected to have clinical applications. It may be important to integrate the 2 systems and construct a universal system that can be used more widely in clinical practice.